Big Rock Partners Acquisition Aktie [WKN DE: A3CQ3Q / ISIN: US6294441000]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Big Rock Partners Acquisition Corp Registered Shs

03.02.22		Pre-market Movers: BON, FB, BPTS, LSPD, SNAP… (RTTNews)
03.02.22		NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules (PR Newswire)
31.01.22		NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules (PR Newswire)
27.01.22		NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant (PR Newswire)
26.01.22		NRx Pharmaceuticals Gets First Safety Report For Its Covid-19 Drug From A Southwestern Hospital (RTTNews)
26.01.22		NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge (PR Newswire)
12.01.22		NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics (PR Newswire)
05.01.22		NRx Seeks Emergency Approval For ZYESAMI To Treat Patients At Immediate Risk Of Death From COVID-19 (RTTNews)
05.01.22		NRx Pharmaceuticals Submits Emergency Use Authorization Application to US Food and Drug Administration for ZYESAMI® (aviptadil) to Treat Patients at Immediate Risk of Death from COVID-19 Despite T... (PR Newswire)
03.01.22		NRx Files Provisional Patent For Stable Compositions Of Aviptadil Suitable For Human Use (RTTNews)
03.01.22		NRx Pharmaceuticals Files Provisional Patent for Stable Compositions of Aviptadil Suitable for Human Use (PR Newswire)
29.12.21		NRx Pharma Files Breakthrough Therapy Designation Request For ZYESAMI (RTTNews)
29.12.21		NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with Remdesivir and Other Approve... (PR Newswire)
22.11.21		Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
05.11.21		NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine P... (PR Newswire)
05.11.21		Pre-market Movers: RWLK, OTRK, EVAX, NRXP, PTON… (RTTNews)
04.11.21		US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure (PR Newswire)
03.11.21		Pre-market Movers: BBBY, RRD, GKOS, TMBR, IRTC… (RTTNews)
02.11.21		NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
14.10.21		Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure (PR Newswire)
13.10.21		Pre-market Movers: WTRH, NEW, RGLS, KOSS, PROC… (RTTNews)
12.10.21		NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil) (PR Newswire)
07.10.21		Pre-market Movers: CYRN, CEI, OSMT, NURO, TTM… (RTTNews)
29.09.21		NRx Pharma: Data Safety Monitoring Board Finds No New Safety Concerns In ACTIV-3b Trial (RTTNews)
29.09.21		NRx Pharmaceuticals Announces Second Favorable Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
27.09.21		NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil) (PR Newswire)
08.09.21		NRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
07.09.21		Pre-market Movers: IRNT, MTL, IFRX, FWP, JAGX, IPHA… (RTTNews)
30.08.21		NRx : Zyesami Phase 2b/3 Trial Result Shows Relief From Respiratory Distress In Critical COVID-19 (RTTNews)
30.08.21		NRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 (PR Newswire)
26.08.21		NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies (PR Newswire)
24.08.21		NRx Pharmaceuticals Announces Closing of $30 Million Private Placement (PR Newswire)
23.08.21		Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary (PR Newswire)
19.08.21		NRx Pharmaceuticals Announces $30 Million Private Placement (PR Newswire)
18.08.21		NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 (PR Newswire)
17.08.21		NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial Update (PR Newswire)
10.08.21		NRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021 (PR Newswire)
09.08.21		NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia (PR Newswire)
04.08.21		MannKind Partners With NRx Pharma To Explore Dry Powder Formulation Of ZYESAMI (RTTNews)
04.08.21		MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform (PR Newswire)
04.08.21		NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions (PR Newswire)
27.07.21		NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia (PR Newswire)
22.07.21		NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory ... (PR Newswire)
19.07.21		NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19 (PR Newswire)
12.07.21		NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine (PR Newswire)
12.07.21		NRx Pharma, Quantum Leap Announce Inhaled ZYESAMIÔ Treatment For COVID-19 Patients (RTTNews)
12.07.21		NRx Pharmaceuticals and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with ZYESAMIÔ (Aviptadil) in the I-SPY COVID Trial (PR Newswire)
06.07.21		NRx Initiates Emergency Use Training And Extends Phase 2/3 Inhaled ZYESAMI Trial In Georgia (RTTNews)
06.07.21		NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia (PR Newswire)
15.06.21		NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI™ (Aviptadil) Expanded Access Protocol (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Nach NVIDIA & Co: Diese beiden Unternehmen könnten den nächsten Aktiensplit erleben

Bitcoin, Ether & Co. in der vergangenen Woche: Wochenbilanz der Kryptowährungen in KW 2

APA - N A C H R I C H T E N Ü B E R B L I C K

Steinmeier setzt Neuwahlen für 23. Februar an

Konkurrenz für D-Wave Quantum: Auf diese Geschäftseinheit von Honeywell hält ein Analyst große Stücke

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	14.01.2025 13:11
Kaufwert:	EUR
	Hinzufügen Speichern